AllogeneTx CEO Change Signals Potential Trouble
🚨! @AllogeneTx just announced that Dr. David Chang will transition from his role as $ALLO President & CEO. The company’s board of directors has elected Zachary Roberts - Allogene’s VP R&D & CMO, as the company’s President and CEO effective 7/1/26. In most cases - drastic changes in a company’s management & C-Suite are usually not a good sign. $XBI
Epigenetic Editing Advances Toward Safer Gene Therapies
1/Here is an excellent article by @TheEconomist which sheds light on a new and promising Gene Editing modality called EpiGenetic Editing. Unlike its older and more clinically mature Gene Editing “siblings” - CRISPR, Base Editing, Prime Editing and RNA Editing,...
Expert Wei Debunks PRME Failure Claims with CRISPR Insight
Here is a great overview by one of the most educated & knowledgeable people on đť•Ź and a personal friend - @zhaoweiasu, in which he rebutted the argument that $PRME has failed to deliver on its business model. As an...
Prime and Base Editing Complement, Not Replace, Each Other
The common theme that “Prime Editing $PRME will eventually replace Base Editing $BEAM and make it obsolete” is completely wrong. An example for their irreplaceable and even complementary rule can be seen in an excellent research published by @eyeMacLaren which...
Gene and Cell Therapies Surge: Over 2,000 Projects in 2026
This excellent @Citeline 📊👇shows the exponential rise in the Gene & Cell Therapy field over the past 30 years. 2026 continues show strength with 2,115 Gene Therapies currently being developed to cure genetic diseases & 2,610 Cell therapies in different...
SANA Adds CD8‑targeted Fusosome SG227 to Pipeline
🚨! $SANA has just reported - in its Q1 ER, that it plans to expand its pipeline by advancing a new preclinical program - SG227. SG227 is a CD8-targeted fusosome that by delivering a genetic material to make BCMA-directed CAR...
Fractyl Secures Dutch CTA for First GLP‑1 Gene Therapy Trial
Fractyl Health today announced that it has received Clinical Trial Application (CTA) authorization in the Netherlands to initiate the Phase 1/2 first-in-human study of RJVA-001 - $GUTS first clinical candidate from its Rejuva 🧵👇 GLP-1 Gene Therapy platform and the...
BEAM Wins TIME 100, Delivers First Gene Base Editing Cure
Congrats to $BEAM on being named as one of @TIME’s 100 most influential & innovative companies that are shaping the world & our future. @beamtx’s leading Gene Editing platform - Base editing, has achieved a significant milestone when KJ Muldoon...
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
NTLA Set to Unveil First In‑Vivo CRISPR Phase 3 Data
Here is a video of me entering my office tomorrow knowing that $NTLA is about to present the first-ever Phase 3 data of an In Vivo (!) CRISPR Gene Editing Program. Somehow - and after @adamfeuerstein’s🧵👇- I have a feeling...
Kailera Leads, SANA Ranks #2 Among Biggest Biotech IPOs
The excellent @biospace 📊👇shows the 5 biggest IPOs in BioTech history. At the top of this list is of course Kailera Therapeutics $KLRA with its $625M blockbuster IPO - the largest public offering in recent years. The one that caught...
MGTX Buys Back XLRP Gene Therapy for $25 M
$MGTX just announced that it has entered into an asset purchase agreement with $JNJ to acquire back its bota-vec Gene Therapy program for the treatment of X-linked retinitis pigmentosa (XLRP) 🧵👇 for an upfront cash payment of $25M & a...
AllogeneTx Stock Plummets After $2 Share Offering
I saw that a lot of people on 𝕏 are surprised by the sharp decline in $ALLO stock price - from $4.3 to $2.2 in one day despite the company’s excellent cema-cel readout 🧵👇. The reason for this decline is...
Weekly Biotech Roundup: Top Insights From X's Best Accounts
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Gene Therapy Poised to Redefine Obesity Treatment Landscape
1/GLP-1 obesity and weight-loss drugs - such as $NVO Ozempic & Wegovy and $LLY Zepbound & Mounjaro have long become a household name - making Obesity the fastest growing market in the BioTech and Pharma ecosystem and generating unprecedented revenues....